Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.
My memory does indeed serve me right. Here is where the flip-flop occurred after VRNG filed their Notice of Appeal first and then the CAFC realigned the parties making GOOG the appellant and VRNG the appellee.
http://www.scribd.com/doc/144727857/Vringo-v-Google-CAFC-Reverses-Order
I'd slept since then, but that was what I remembered. Had to find it to make sure I wasn't losing my mind too. LOL
I'm relying on my memory, but as I recall VRNG filed their notice first followed by GOOG filing to have the parties flipped. Either way, the case was going up on appeal as BOTH parties had issues that happened at the trial court that they wanted to raise on appeal. There is only one appellant, and after the flip flop that appellant became GOOG regardless of what happened before.
spookytrades Wednesday, 01/27/16 10:26:18 AM
Re: JJSeabrook post# 64077
Post # of 64079
unfortunately he didn't understand or recall that VRNG appealed to CAFC FIRST - which you cleared up for him and me - and he implies I am spreading "false information" - which according to you - I was not incorrect... VRNG appealed first. In the end BOTH parties appealed to CAFC if I understand what you said...
I didn't see the prior post. I was just responding to the first sentence of yours:
"VRNG was NOT the company who asked for an appeal at the CAFC in regards to laches, it was Google."
Must have lost something in the context. IF you meant that the central issue of the appeal was NOT laches, then I'd totally agree with that.
JJ
Rain, Google did NOT appeal the laches ruling, VRNG did. VRNG was the party that lost the laches ruling. Why would GOOG possibly have appealed a ruling they had won on at the trial court level?
BOTH parties had points of error that they raised, which is common in an appeal. Whether you be the appellant (GOOG in this case) or appellee (VRNG), you can still raise points of error of your own while defending the points of error raised by the other party.
Actually, as I recall, VRNG was the first to file the Notice of Appeal and was initially named as the appellant. That got flipped and GOOG then became the appellant even though they filed their notice after VRNG.
Had VRNG survived the obviousness issue the CAFC found, the Court would have had to address VRNG's laches error they raised on appeal. After whacking VRNG that became a moot point. I believe that if you will go back and read the appeal you will find that VRNG was indeed the party that raised laches, a point which they were ruled against at the trial court level. However, in the scheme of things it really doesn't matter.
Rainmaker80 Wednesday, 01/27/16 07:20:55 AM
Re: None
Post # of 64072
VRNG was NOT the company who asked for an appeal at the CAFC in regards to laches, it was Google.
This statement that as made that 'VRNG asked for the appeal at the CAFC", and thus implying a misjudgement and failure by VRNG management, is CATEGORICALLY FALSE.
A simple search on the internet, a review of the pacer documents (which states the plaintiff and defendant at the CAFC) would/ will confirm this for anyone.
We suggest, that whenever LONGS read a comment that states something about this company as fact, that you 'fact check' rather than taking anything at face value (if no source is included). Similar to when others are talking about financial statements, confirm via your own review of that company's publicly disclosed information.
Here is a link that confirms that VRINGO was the DEFENDANT at the CAFC and NOT the plaintiff (which was Google ie Google filed the appeal). Again, I suggest everyone confirm this via the pacers on VRNG24's blog as well.
http://arstechnica.com/tech-policy/2014/01/court-orders-google-to-pay-1-36-of-adwords-revenue-for-infringing-patents/
Key Quote below:
"Jennifer Polse, Google's lead patent lawyer on the Vringo case, said that the company has already appealed the jury verdict and will appeal today's royalty award as well. "We believe strongly in our pending appeal in this matter, and we anticipate seeking Federal Circuit review of today's decision as well," said Polse in an e-mail"
It is highly imperative that any LONG on these boards verify statements by others about VRNG via their own diligence.
All LONGS - As mentioned the trading of this security and a number of others in the IP space is under scrutiny for legitimate reasons. Please be vigilant in your review of information on chat boards and always refer to information disclosed by VRNG as your one and only true source of information.
GLTA LONGS
Venaxis (APPY) (.25)Enters Merger Agreement with Strand LS
Venaxis®, Inc. (Nasdaq: APPY) announced that it has entered into a series of agreements for a transaction with Strand Life Sciences Private Limited (Strand LS) and its shareholders. Strand LS is a privately-held, global genomics and bioinformatics company. Strand LS operates clinical reference labs in the US through its wholly owned subsidiary Strand Genomics, Inc., (Strand U.S.) and directly in India, providing testing and lab services in India and other world-wide markets. Strand LS has commercialized a next generation sequencing (NGS) based, targeted, multi-gene, pan-cancer diagnostic panel in select international markets and has engaged in initial commercialization activities in the United States.
Assuming participation by 100% of the Strand LS shareholders, the effect of the transaction will be that Strand LS shareholders and the employees and directors who are option-holders in Strand LS will own directly and beneficially approximately 68% of the combined enterprise and the current shareholders of Venaxis will own approximately 32%. Due to Indian tax and financial regulations, the transaction is being structured as purchases, by Venaxis, of the Strand LS shares from the Strand LS shareholders, followed by an immediate re-investment of those sale proceeds, by the Strand LS shareholders, into Venaxis Common Stock.
To comply with certain long-term holding period requirements under Indian tax law, the transaction is expected to be completed in two closings. The first closing will occur upon receipt of the necessary approvals from the Venaxis shareholders, receipt of all other required approvals and satisfaction of identified closing conditions. The second closing will occur approximately six months later. At each closing, Venaxis will enter into resale registration rights agreements with the Strand LS shareholders participating in such closing. The boards of each company have unanimously approved the transaction, however this transaction is subject to Venaxis shareholder approval.
At the first closing, Venaxis will own a majority of the shares of Strand LS, will change its name to Strand Life Sciences, and will change its NASDAQ trading symbol. As part of the first closing, following Venaxis shareholder approval, a Venaxis subsidiary will enter into an asset purchase agreement with Strand U.S. in which it will acquire substantially all of the assets and liabilities of Strand U.S. in exchange for cash consideration paid to Strand U.S.
Advancing to the execution of the agreements with Strand LS, its shareholders and Strand U.S. represents the outcome of an extensive strategic process initiated by Venaxis in early 2015. Venaxis has also commenced, and expects to continue to attempt to locate a partner or other third-party interested in advancing development and or commercial activities of the Venaxis appendicitis portfolio. Aligning Strand Life Sciences' proven technological expertise in genomic profiling, bioinformatics and data curation with Venaxis' financial resources, NASDAQ public listing and key management personnel provides an opportunity for Strand Life Sciences to continue to commercialize its global business model towards what is believed to be a valuable enterprise for the combined shareholders.
Following approval by the Venaxis shareholders and satisfaction of the other closing conditions, at the first closing, Dr. Vijay Chandru, the co-founder and current Executive Chairman of Strand LS, will serve as Executive Chairman of the combined company's Board of Directors, Steve Lundy will become the Chief Executive Officer of the combined company and Jeff McGonegal will continue as CFO. The initial combined board will consist of seven members with four from Strand LS and three from Venaxis.
Commenting on the transaction, Dr. Vijay Chandru said, "On behalf of the Strand LS shareholders, we believe that this transaction represents an attractive opportunity for Strand Life Sciences, as an agile innovator in clinical genomics, to combine forces with Venaxis, a public company in the United States with experienced executives and board members to help it rapidly expand market adoption of StrandAdvantage™ and other future product offerings."
"We are pleased to announce this transaction and are excited by the significant opportunity we believe it presents for shareholders of Venaxis and Strand LS," said Steve Lundy, Chief Executive Officer of Venaxis, Inc. "The combined company will benefit from Strand Life Sciences' 15 year successful history of technological expertise in genomic profiling, bioinformatics and data curation. Our initial focus will be to improve patient outcomes through the use of the StrandAdvantage pan-cancer gene panel, which was commercially launched in the United States in 2015. The combined company is expected to be focused on the continued commercialization of StrandAdvantage, as well as the development of additional oncology-related diagnostics."
Raymond James & Associates, Inc. and Oppenheimer & Co. Inc. are acting as joint financial advisors to Strand LS and Baker & Hostetler LLP is acting as legal counsel for Strand LS. Ballard Spahr LLP is acting as legal counsel to Venaxis.
Conference Call Venaxis and Strand LS will host an investor conference call to discuss the transaction on Wednesday, January 27, 2016, at 8:30 a.m. ET. The conference call will be hosted by Steve Lundy, President and CEO of Venaxis, Inc.
A live audio webcast will be accessible via the Investor Relations section of the Venaxis website, www.venaxis.com/webcast/. Participants and investors may also access the conference call by dialing 1-888-329-8893 (U.S.) or 1-719-325-2315 (Toll – International).
A replay of the call will be available approximately an hour after the end of the conference call on Venaxis' website. To access the webcast, please visit the investor relations section of the Venaxis website at www.venaxis.com/webcast/.
Sure would like to see this break 1.10 with some volume.
SNGX Corporate presentation 1/15/16:
Retractable Technologies, Inc. Declares Dividends to Series I and II Class B Preferred Stock Shareholders
Date : 01/11/2016 @ 5:36PM
Source : Business Wire
Stock : Retractable Technologies, Inc. (RVP)
Quote : 2.91 -0.01 (-0.34%) @ 4:00PM
Retractable Technologies, Inc. Declares Dividends to Series I and II Class B Preferred Stock Shareholders
Print
Alert
Retractable Tech (AMEX:RVP)
Intraday Stock Chart
Today : Monday 11 January 2016
Click Here for more Retractable Tech Charts.
Retractable Technologies, Inc. (NYSE MKT: RVP) announced today that its Board of Directors has declared dividends to holders of its Series I Class B and Series II Class B Convertible Preferred Stock in the amounts of $12,312.50 and $43,101.37, respectively. The dividend amount is $0.125 per share for Series I Class B shareholders and $0.25 per share for Series II Class B shareholders. Dividends have accrued at 10% per annum and cover amounts in arrears from and including October 1, 2015 through date of conversion or December 31, 2015, whichever is applicable. The dividends will be paid on February 1, 2016 to shareholders of record as of the close of business on January 21, 2016.
RTI manufactures and markets VanishPoint® and Patient Safe® safety medical products. The VanishPoint® syringe, blood collection, and IV catheter products are designed to prevent needlestick injuries and product reuse by retracting the needle directly from the patient, effectively reducing exposure to the contaminated needle. Patient Safe® syringes are uniquely designed to reduce the risk of bloodstream infections resulting from catheter hub contamination. RTI's products are distributed by various specialty and general line distributors.
For more information on RTI, visit our website at www.vanishpoint.com.
Forward-looking statements in this press release are made pursuant to the safe harbor provision of the Private Securities Litigation Reform Act of 1995 and reflect our current views with respect to future events. We believe that the expectations reflected in such forward-looking statements are accurate. However, we cannot assure you that such expectations will materialize. Our actual future performance could differ materially from such statements.
Factors that could cause or contribute to such differences include, but are not limited to: our ability to maintain liquidity; our maintenance of patent protection; the impact of current and future Court decisions regarding current litigation; our ability to maintain favorable third party manufacturing and supplier arrangements and relationships; our ability to quickly increase capacity in response to an increase in demand; our ability to access the market; our ability to maintain or lower production costs; our ability to continue to finance research and development as well as operations and expansion of production; the impact of larger market players, specifically Becton, Dickinson and Company, in providing devices to the safety market; and other risks and uncertainties that are detailed from time to time in RTI's periodic reports filed with the U.S. Securities and Exchange Commission.
View source version on businesswire.com: http://www.businesswire.com/news/home/20160111006602/en/
Retractable Technologies, Inc.
Douglas W. Cowan, 888-806-2626 or 972-294-1010
Vice President and Chief Financial Officer
At least we know someone with the company is living and breathing. LOL
An 85-year-old man was requested by his Doctor to have a sperm count as part of his physical exam.
The doctor gave the man a jar and said, "Take this jar home and bring back a semen sample tomorrow."
The next day the 85-year-old man reappeared at the doctor’s office and gave him the jar, which was as clean and empty as on the previous day.
The doctor asked what happened and the man explained, "Well, doctor, it’s like this — first I tried with my right hand, but nothing. Then I tried with my left hand, but still nothing.
Then I asked my wife for help. She tried with her right hand, then with her left, still nothing. She tried with her mouth, first with her false teeth in, then with her false teeth out, still nothing.
We even called up Arleen, the gorgeous lady next door and she tried too, first with both hands, then an armpit, and she even tried squeezing it between her knees, but still nothing."
The doctor was shocked and said, "You asked your neighbor?"
.
.
.
.
.
.
.
The old man replied, "Yep, none of us could get the jar open!"
OMG! LMAO
SHORENUFFSTUFF Member Level Thursday, 01/07/16 02:54:29 PM
Re: None
Post # of 21895
I was on my way home from work, and saw my midget neighbor waiting for the bus...
I said "hop in, I'll give you a lift!"
He gave me the finger and told me to fuck off.
So I just zipped up my backpack and continued walking.
63,747 shares went off at the .86 ask. Nice buy!
AXN
Nice bounce to .865. No news.
Evidently the letter fell on deaf ears. LOL
FLI CHARGE ANNOUNCES NEW PRODUCT LINE TO BE UNVEILED AT CES 2016
Print
Alert
Product Demonstration to Feature Solutions for the Automotive, Furniture, Power Tool and Consumer Markets
To View Product Lineup visit: http://bit.ly/1UWX6ak
NEW YORK - December 22, 2015 - Fli Charge, a company developing an ecosystem of wire-free power solutions to transform the way people power their everyday lives, today announced that it will be providing attendees of the 2016 International Consumer Electronic Show (CES) with a preview of its new product line as well as products developed with several of its partners.
Attendees can visit Fli Charge at CES in the North Hall of the Las Vegas Convention Center at Booth 6519 from January 6-9, 2016.
Fli Charge's product line includes power pads, charging cases for the most popular mobile devices, and universal adapters for all other USB powered devices including smartphones, tablets, smart watches, cameras, fitness trackers, gaming controllers, portable speakers, Bluetooth headsets and many other everyday devices.
A key advantage of Fli Charge's patented, conductive, wire-free charging technology is that each Fli Charge power pad is compatible with every Fli Charge case and universal adaptor. Additionally, Fli Charge's revolutionary power pads are capable of powering multiple devices at the same time with cumulative power requirements in excess of 150 watts.
All of the products in the Fli Charge ecosystem maintain a consistent design language and finish. With Fli Charge's partners and licensees in mind, Fli Charge has developed products that allow for seamless integration of custom branding and white-label opportunities.
In addition, Fli Charge will be demonstrating its technology integration opportunities for original equipment manufacturers and original design manufactures (OEM/ODM). By embedding Fli Charge's wire-free "constellation" into laptops, tablets, power tools, and other devices, Fli Charge allows partners to quickly differentiate their products and improve product usability by offering consumers an innovative, cost effective and convenient way to deliver power.
At CES, Fli Charge and its partners, including MITO Corporation, Bretford Manufacturing, Inc. and The Worden Company, will demonstrate the growing product ecosystem that includes automotive, home, school and office applications. These demonstrations will exhibit the impressive scalability, flexibility and interoperability of the patented Fli Charge technology. Attendees will see how Fli Charge products can seamlessly integrate into everyday life, whether it be at home, school, the office, a coffee shop, a work site, in the car or anywhere else in between.
In addition to these demonstrations, the Fli Charge booth will include a dedicated wire-free charging station where attendees can use Fli Charge's products first-hand to charge their mobile devices simultaneously.
Members of Fli Charge's management team will be present at the conference. Media, partners, licensees, resellers, investors and other interested parties who wish to request a private meeting may do so at: www.FliCharge.com/contact.
To learn more about Fli Charge, visit www.FliCharge.com or http://bit.ly/1UWX6ak.
Macintosh HD:Users:Vringo:Desktop:Postcard_Back.jpg
About Fli Charge
Fli Charge designs, develops, manufactures and markets wire-free conductive power and charging solutions. Fli Charge's patented technology is the only wire-free power solution that is fully interoperable between different devices ranging from smartphones to power tools. Fli Charge's wire-free power solution can simultaneously power multiple devices on the same pad no matter their power requirements or positions on the pad.
Fli Charge's conductive technology is the most efficient wire-free power solution and can be adapted to work with virtually all battery-powered and DC powered devices on the market. Fli Charge's products are easily integrated into your everyday life and are simple to use. For more information, visit: www.FliCharge.com
About CES
CES is the world's gathering place for all who thrive on the business of consumer technologies. It has served as the proving ground for innovators and breakthrough technologies for almost 50 years-the global stage where next-generation innovations are introduced to the marketplace. As the largest hands-on event of its kind, CES features all aspects of the industry. And because it is owned and produced by the Consumer Technology Association (CTA)TM - formerly the Consumer Electronics Association (CEA)® - the technology trade association representing the $285 billion U.S. consumer technology industry, it attracts the world's business leaders and pioneering thinkers to a forum where the industry's most relevant issues are addressed.
About Vringo, Inc.
Vringo, Inc. is engaged in the innovation, development and monetization of intellectual property as well as the commercialization and distribution of wire-free charging and rugged computing devices. Vringo's intellectual property portfolio consists of over 600 patents and patent applications covering telecom infrastructure, internet search, ad-insertion, mobile and wire-free charging technologies. Vringo's subsidiary Fli Charge is dedicated to the licensing and commercialization of wire-free charging technologies. Vringo's subsidiary Group Mobile is dedicated to the marketing and sale of rugged computing devices. For more information, visit: www.vringo.com.
Forward-Looking Statements
This press release includes forward-looking statements, which may be identified by words such as "believes," "expects," "anticipates," "estimates," "projects," "intends," "should," "seeks," "future," "continue," or the negative of such terms, or other comparable terminology. Forward-looking statements are statements that are not historical facts. Such forward-looking statements are subject to risks and uncertainties, which could cause actual results to differ materially from the forward-looking statements contained herein. Factors that could cause actual results to differ materially include, but are not limited to: our inability to license and monetize our patents, including the outcome of the litigation against ZTE and other companies; our inability to recognize the anticipated benefits of the acquisition of IDG, which may be affected by, among other things, competition, our ability to secure advantageous licensing and sales agreements, market acceptance of IDG's technology, potential technology obsolescence, protection of intellectual property rights and potential liability risks that are inherent in the marketing and sale of products used by consumers; our inability to monetize and recoup our investment with respect to patent assets that we acquire; our inability to develop and introduce new products and/or develop new intellectual property; our inability to protect our intellectual property rights; new legislation, regulations or court rulings related to enforcing patents, that could harm our business and operating results; unexpected trends in the mobile phone and telecom infrastructure industries; our inability to raise additional capital to fund our combined operations and business plan; our inability to maintain the listing of our securities on a major securities exchange; the potential lack of market acceptance of our products; potential competition from other providers and products; our inability to retain key members of our management team; the future success of Infomedia and our ability to receive value from its stock; our ability to continue as a going concern; our liquidity and other risks and uncertainties and other factors discussed from time to time in our filings with the Securities and Exchange Commission ("SEC"), including our annual report on Form 10-K filed with the SEC on March 16, 2015. Vringo expressly disclaims any obligation to publicly update any forward-looking statements contained herein, whether as a result of new information, future events or otherwise, except as required by law.
Contact Information
Media Inquiries: media@FliCharge.com
Licensing, Partnership & Reseller Inquiries: sales@FliCharge.com
General Inquiries: info@FliCharge.com
Investor Inquiries: info@vringoinc.com
Yes, I was only referring to the named insiders I listed. Didn't realize it was confusing. Thanks!
Insiders own 5.15%. Looks like Cliff is the 4th largest shareholder of VRNG.
1/23/15 Spiegel 100,000
1/23/15 Conrad 100,000
1/23/15 Engelman 100,000
1/23/15 Van 100,000
1/23/15 Stout 100,000
1/23/15 Berger 1,155,856
6/30/14 Perlman 675,542
9/30/14 Lang 2,753,577
How about now with POST SPLIT (1:10) shares?
Spiegel 10,000
Conrad 10,000
1/23/15 Van 10,000
1/23/15 Stout 10,000
Berger 115,585
Perlman 67,554
Lang 275,357
Engelman 10,000
12/16/15 Weinstein 71,668 (4th Largest Shareholder)
TOTAL INSIDER SHARES 580,164
O/S 11.27M
% of insider ownership= 5.15%
That's what I come up with.
Major Direct Holders (Forms 3 & 4) as of September 30, 2014
Holder Shares Reported
LANG ANDREW KENNEDY 2,753,577 Sep 30, 2014
BERGER ALEXANDER R. 467,385 Jun 30, 2014
PERLMAN ANDREW D 675,542 Sep 30, 2014
SINCLAIR H. VAN 274,454 Sep 30, 2014
ENGELMAN JOHN 186,576 Sep 30, 2014
http://finance.yahoo.com/q/mh?s=VRNG+Major+Holders
Hopefully it will motivate them to release SOMETHING to their shareholders.
Cliff Weinstein share purchases:
12/9/15 5000 @ 2.2406
12/11/15 13,342 @ 2.318
12/14/15 6658 @ 2.23
12/15/15 15,000 @ 2.24
TOTAL 40,000 shares.
No, they're not lapsed. All the ZTE cases filed worldwide would have been booted right off the bat if the patents were lapsed. Don't waste your time looking.
Be nice to hear something before EOY.
I have NO idea. That's a mystery as perpetual as the licenses ZTE got.
loci Wednesday, 12/09/15 03:27:43 PM
Re: None
Post # of 63073
JJ in your opinion why they didn't wait the nda ruling?
SNGX definitely NEEDS a comeback! NO question about that! I, for one, hope like hell they have one!
The 8-K isn't clear to me that the $21.5M cash payment is all there is going to be, although that may 100% be the case. The bad thing for shareholders is it will be quite some time before we're 100% sure that's all there is to it. Even if/when they issue a PR, they're not going to provide any more info than they already have in their 8-K as all the other terms of the settlement are confidential. When they do release a PR we're still going to be sittin here thinkin "That still didn't tell us shit, other than there's a $21.5M payment and all the ZTE litigation is over and done with."
I'm in the camp that's dissapointed if $21.5M settled all the ZTE cases, but that may be where it stands. I don't know with 100% certainty either way. I still hold out hope that there is more to it than we know.
I don't know how the Nokia agreement was drafted but you'd think that Nokia wouldn't receive anything until VRNG had a NET recovery of $22M, not a gross recovery. I believe all attorneys fees and costs would be taken out before the $22M figure starts adding up at all, and obviously the $21.5M isn't net recovery. Nokia is still along way from receiving any funds is my guess.
spookytrades Tuesday, 12/08/15 07:38:01 AM
Re: None
Post # of 62891
INTERESTING TWEET "Interesting the settlement was just below the 22 million required to Kick In the Nokia 35% clause" Does anyone know if 22 million was the cutoff? If so then did they just screw NOKIA ?
$VRNG 2/2
— Sergiy Nazarko (@Begemotus) December 8, 2015
Interesting the settlement was just below the 22 million required to Kick In the Nokia 35% clause
I would imagine he had some comments within his own circle after being reversed, but nothing we'll ever be made aware of publicly.
piratica Monday, 12/07/15 10:08:22 AM
Re: None
Post # of 62703
JJS, RED ANGUS, VRNG24, EVERYONE, DID JUDGE RAYMOND JACKSON EVER COMMENTED AT ALL HOW THIS FIASCO TURNED OUT AT THE END??? THANK YOU IN ADVANCE FOR YOUR RESPONSE. "STILL HANGING ON" GLTA
Aoxing Pharma Announces Opening Of Government Funded Drug Research Center
PR Newswire Aoxing Pharmaceutical Company, Inc.
2 hours ago
????
JERSEY CITY, N.J., Dec. 4, 2015 /PRNewswire/ -- Aoxing Pharmaceutical Company, Inc. (NYSE MKT: AXN) ("Aoxing Pharma"), a specialty pharmaceutical company focusing on research, development, manufacturing, and distribution of narcotic, pain-management, and addiction treatment pharmaceuticals, today announced the inauguration of its new Narcotic and Psychotropic Drug Research Center. Construction of the Center was funded by the Reform and Development Commission of Hebei Province in China along with Aoxing Pharma's Chinese subsidiary, with a total investment of US$2.15 million.
This state-of-the art Research Center occupies 2200m2, and meets current GLP and GMP standards. The Center will provide facilities for narcotic and psychotropic drug research and development, including chemical synthesis, transdermal patch formulation, pilot manufacturing, quality review and analytical labs. The Center is outfitted with the latest technology, to offer an optimal research environment to the research scientists at Aoxing Pharma.
"We are delighted by the inauguration of the new R&D Center, and are honored to receive this powerful endorsement by the Chinese government," said Mr. Zhenjiang Yue, the Chairman and CEO of Aoxing Pharma. "The government contributed to the funding of this project in recognition of our company's strong commitment to the narcotic drug and psychiatric treatment business. Government endorsement of our efforts can also be seen in our recent receipt of authorization from the China FDA (CFDA) to initiate four drug programs, including Lorcaserin Hydrochloride tablets and Lorcaserin Hydrochloride API (active pharmaceutical ingredient), weight-reduction drugs for overweight and obese patients, as well as Caffeine tablets (for swallowing) and Caffeine buccal tablets (for dissolving in the mouth), for the management of mental fatigue and headache. With government approval and our new government-funded research facility, we are well positioned to quickly introduce such products into the Chinese pharmaceutical market."
About Aoxing Pharmaceutical Company, Inc.
Aoxing Pharmaceutical Company, Inc. is a US incorporated specialty pharmaceutical company with its operations in China, specializing in research, development, manufacturing and distribution of a variety of narcotics and pain-management products. Headquartered in Shijiazhuang City, outside Beijing, Aoxing Pharma has the largest and most advanced manufacturing facility in China for highly regulated narcotic medicines. Its facility is one of the few GMP facilities licensed for the manufacture of narcotic medicines by the China Food and Drug Administration ("CFDA"). For more information, please visit: www.aoxingpharma.com.
Safe Harbor Statement from Aoxing Pharmaceutical Company, Inc.
Certain statements made in this press release are forward-looking and are made pursuant to the safe harbor provisions of the Securities Litigation Reform Act of 1995. Such statements involve risks and uncertainties that may cause actual results to differ materially from those set forth in these statements. All forward-looking statements included herein are based upon information available to the Company as of the date hereof and, except as is expressly required by the federal securities laws, the Company undertakes no obligation to update or revise any forward-looking statements, whether as a result of new information, changed circumstances or future events or for any other reason. To the extent that any statements made here are not historical, these statements are essentially forward-looking. Undue reliance should not be placed on forward-looking information. The economic, competitive, governmental, technological and other risk factors identified in the Company's filings with the Securities and Exchange Commission, specifically, Item 1A, "Risk Factors," in the Form 10-K for the year ended June 30, 2015, may cause actual results or events to differ materially from those described in the forward looking statements in this press release. The Company undertakes no obligation to publicly update or revise any forward-looking statements, whether because of new information, future events, or otherwise.
To view the original version on PR Newswire, visit:http://www.prnewswire.com/news-releases/aoxing-pharma-announces-opening-of-government-funded-drug-research-center-300188105.html
The emails were provided in a discovery response. I don't think that was EVER made public, and may NEVER be made public. That decision has yet to be made, but I don't think he'll find it.
So G is only complaining about multiple emails that occurred during a single day. Not some ongoing thing like we might have expected. Wonder what's in there? Inquiring minds would like to see them. LOL
Yes. Not near enough volume to come close to dumping those shares.
Look at all the 424B3's at the top of the posts. It ain't hidden.
.55 may be the bounce zone. Too bad it's such a diluted POS.
Here it is: JJSeabrook Member Level Monday, 11/16/15 05:31:23 PM
Re: nfp post# 62332
Post # of 62642
Here's the vote: http://www.conferencecalltranscripts.org/8/summary/?id=2190319
ASTI..just had a form EFFECT for 28M shares yesterday on an S3 and also filed an S1 yesterday to register another 30M shares. Don't know that I'd camp here too long. Good luck! Great news for them today!
Just exactly what was it that you "called?" This had a 1:10 R/S that went into effect today and is up about 5.7% @ 3.30. You call that a huge gain? LOL
BLULLISH Member Level Monday, 11/30/15 02:30:25 PM
Re: None
Post # of 62553
Mega Congrats to everyone-that loaded When I CALLED THIS AT BOTTOM-(VRNG) HUGE GAINS TODAY...
I SPECIALIZE 1000%-5000% BREAKOUTS
VRNG shares just showed back up in my TDA account a few minutes ago so if you have TDA you can both buy and sell shares right now. Other brokers may be a little behind TDA, and some may have had their shares show up in their accounts before TDA accounts. If your shares don't show up yet they will likely show later today or tomorrow. You can buy shares any time, but you can only sell your shares once they show up in your trading account.
soundincrest Monday, 11/30/15 09:53:39 AM
Re: spookytrades post# 62526
Post # of 62535
When Can you trade VRNG?
VRINGO, INC. ANNOUNCES REVERSE STOCK SPLIT
By GlobeNewswire, November 25, 2015, 02:00:00 PM EDT
Vote up
loading
A A A
NEW YORK - November 25, 2015 - Vringo, Inc. (NASDAQ:VRNG), a company engaged in the innovation, development and monetization of intellectual property as well as the commercialization and distribution of wire-free charging and rugged computing devices, today announced the that effective at 5:00 pm, Eastern Time, on November 27, 2015 ("Effective Time"), the Company will effect a one-for-ten reverse stock split of its outstanding common stock. The Company's common stock will open for trading on The NASDAQ Capital Market on November 30, 2015 on a post-split basis.
The reverse stock split is intended to increase the per share trading price of the Company's common stock to satisfy the $1.00 minimum bid price requirement for continued listing on The NASDAQ Capital Market. As a result of the reverse stock split, every ten shares of the Company's common stock issued and outstanding on the Effective Time will be consolidated into one issued and outstanding share, except to the extent that the reverse stock split results in any of the Company's stockholders owning a fractional share, which would be rounded up to the next highest whole share. In connection with the reverse stock split, there will be no change in the nominal par value per share of $0.01.
Trading of the Company's common stock on The NASDAQ Capital Market will continue, on a split-adjusted basis, with the opening of the markets on Monday, November 30, 2015, under the existing trading symbol "VRNG" and under a new CUSIP number 92911N302. The reverse stock split reduces the number of shares of the Company's common stock outstanding from approximately 112.7 million pre-reverse split shares to approximately 11.3 million post-reverse split.
The Company has retained its transfer agent, American Stock Transfer & Trust Company, LLC ("AST"), to act as its exchange agent for the reverse stock split. AST will provide stockholders of record as of the Effective Time a letter of transmittal providing instructions for the exchange of their stock certificates. Stockholders owning shares via a broker or other nominee will have their positions automatically adjusted to reflect the reverse stock split, subject to brokers' particular processes, and will not be required to take any action in connection with the reverse stock split.
The reverse stock split was approved within a range of one-for-two to one-for-ten by the Company's stockholders at the 2015 Annual Meeting of Stockholders held on November 16, 2015 and the specific ratio of one-for-ten was subsequently approved by the Company's Board of Directors. For more information regarding the reverse stock split, please refer to the Company's definitive proxy statement filed with the Securities and Exchange Commission on Schedule 14A on September 25, 2015.
About Vringo, Inc.
Vringo, Inc. is engaged in the innovation, development and monetization of intellectual property as well as the commercialization and distribution of wire-free charging and rugged computing devices. Vringo's intellectual property portfolio consists of over 600 patents and patent applications covering telecom infrastructure, internet search, ad-insertion, mobile and wire-free charging technologies. Vringo's subsidiary fliCharge is dedicated to the licensing and commercialization of wire-free charging technologies. Vringo's subsidiary Group Mobile is dedicated to the marketing and sale of rugged computing devices. For more information, visit: www.vringo.com.
Forward-Looking Statements
Read more: www.nasdaq.com/press-release/vringo-inc-announces-reverse-stock-split-20151125-00528#ixzz3sXF8vCgx
This Google intervention, in the scheme of things, really doesn't stack up to mean squat in the overall scheme of things in the present cases in NY against ZTE as Kaplan will be acting as both Judge and Jury. Google intervened for the sole purpose of keeping the emails from going public, or at least the portions of them that relate directly to Google. They will still be used in these SDNY cases, as needed, but Google may very well keep them from going public. All the ruckus by V over public or non-public seems to me to be pointed for use in some other venue on these emails. As a shareholder it's not something that really matters to me one way or the other in the ZTE cases in SDNY.
As for the rule on meet and confer, someone should have picked up the phone and made the call to Google's counsel. Would it have changed anything? Probably not in the slightest, but the rules are the rules. There were emails on it so it's not as if there was no communication on it. G's counsel clearly stated that G was not going to agree to de-designate the documents so not sure Kaplan will get his shorts all in a wad because they didn't talk on the phone. Again, the rule is the rule so he may not be pleased in the manner in which it took place. Some judges are total sticklers on 100% compliance with the rules. Kaplan will have to address the violation by V because it has been raised. May result in a warning to V's counsel, but I don't think anything more than that. This part of it is just a side-show outside of the main event to me. If this were a circus this wouldn't even get inside the tent. LOL
Just my lay opinions as usual.
Rainmaker80 Tuesday, 11/17/15 08:47:17 AM
Re: None
Post # of 62350
What surprised me with that google document was that within it, it says VRNG did not have a meet and confer with them, even though civil procedure requires it prior to making a claim to the court.
I am not a lawyer so I am not sure of what the rationale here was by V counsel but we have seen these types of errors before. If that is the process, why would they:
1. Ignore it, as Kaplan will have expected them to have such a meeting and I would think, suggest they do that first (thus this delay was pointless and all brought about by Vrng counsel, and just brings further delay on this topic-which i guess may not matter as it won't delay trial)
2. And, therefore assume that Kaplan would even side with them if that is indeed the procedure. Again, I am not a lawyer and perhaps JJS who I know has some legal knowledge, may want to wade it.
I am not impressed with VRNG when they are resorting to playground tactics for reaction vs fact based strategies. Seems like it is legitimate that they want the emails open but I just don't get how basics of procedure like this are missed by outside counsel and a group of internal counsel who are being paid alot of money to do ONE THING....
JJS would like to hear your views on this.